Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Tax Provisions (2016 - 2025)

Amphastar Pharmaceuticals has reported Tax Provisions over the past 13 years, most recently at -$21.2 million for Q4 2025.

  • Quarterly results put Tax Provisions at -$21.2 million for Q4 2025, down 453.02% from a year ago — trailing twelve months through Dec 2025 was -$3.1 million (down 110.55% YoY), and the annual figure for FY2025 was -$3.1 million, down 110.55%.
  • Tax Provisions for Q4 2025 was -$21.2 million at Amphastar Pharmaceuticals, down from $4.2 million in the prior quarter.
  • Over the last five years, Tax Provisions for AMPH hit a ceiling of $14.0 million in Q3 2023 and a floor of -$21.2 million in Q4 2025.
  • Median Tax Provisions over the past 5 years was $5.8 million (2021), compared with a mean of $4.9 million.
  • Biggest five-year swings in Tax Provisions: skyrocketed 7560.0% in 2021 and later crashed 453.02% in 2025.
  • Amphastar Pharmaceuticals' Tax Provisions stood at $3.5 million in 2021, then soared by 107.69% to $7.3 million in 2022, then plummeted by 35.9% to $4.7 million in 2023, then increased by 28.35% to $6.0 million in 2024, then crashed by 453.02% to -$21.2 million in 2025.
  • The last three reported values for Tax Provisions were -$21.2 million (Q4 2025), $4.2 million (Q3 2025), and $8.3 million (Q2 2025) per Business Quant data.